Game-changing non-invasive diagnostic solutions to be showcased at MEDICA 2023
Menu

08.11.2023

ABHI Association of British HealthTech Industries Ltd.

Game-changing non-invasive diagnostic solutions to be showcased at MEDICA 2023

UK based diagnostics technology company Testcard will unveil their cutting-edge non-invasive diagnostic solutions at MEDICA 2023 designed to make testing more accessible for consumers and in clinical settings.

As a participant in the ABHI UK Pavilion, Testcard will highlight its innovative technology that transforms a mobile device into a clinical-grade scanner, revolutionising the field of diagnostics.

At MEDICA 2023, the company will showcase its three primary areas of focus. This includes their revolutionary at-home UTI test kit, boasting accuracy comparable to urine tests performed in clinical settings. When coupled with the smartphone app, it allows users to obtain immediate accurate test results from the comfort of their own home. The technology directly integrates with individual suppliers to maintain a complete end-to-end pathway, back to the supplier for treatment.

Testcard has also developed advanced technical solutions for patient screening, helping identify individuals at risk of serious illnesses. By streamlining the process and enabling at-risk patients to test at home, healthcare providers can promptly allocate resources to those in need, optimising GP and laboratory time.

In collaboration with Guys & St Thomas NHS Foundation Trust (GSTT) and SureScreen Diagnostics, the company has launched the revolutionary ClearScreen technology that digitalises point of care rapid diagnostic testing including lateral flow tests.

Testcard's expanding test portfolio, in partnership with market leading manufacturer SureScreen Diagnostics includes Single Covid, Covid/Flu dual test, Covid/Flu/RSV Triple test, Single RSV, Pregnancy, Strep A, CRP, D-Dimer, Troponin, and Monkeypox, contributing to quicker, more efficient healthcare pathways.

TestCard’s Chief Scientific Officer Dr. Andrew Botham said: “Rapid diagnostic testing helps to ease the pressures on health systems. Test results can be generated sooner and acted upon immediately, while mitigating risk for everyone. It also improves the patient pathway with a more effective patient triage, reducing delays with test results. Testcard is excited to be joining ABHI at MEDICA 2023 to showcase our cutting-edge range of technologies designed to transform the fast-growing field of diagnostics, and we look forward to connecting with partners in the region.”

Testcard's platform technology reduces the need for traditional testing, reducing the hassle of multiple appointments, lengthy wait times, and lab fees. The focus on immediacy and accessibility empowers users to receive accurate test results at home or in clinical settings while seamlessly integrating into electronic patient record systems for effective treatment.

In the last year, TestCard has signed a major partnership agreement with Roche Diagnostics, one of the biggest global diagnostics companies. Their technology has also garnered recognition, with TestCard winning multiple awards, including the Digital Health Award, the Shift.ms Digital Award, and the Royal Society of Chemistry Emerging Technologies Competition.

TestCard is a platform technology currently in partnership with Superdrug, the NHS and Roche Diagnostics that is revolutionising healthcare by increasing the accessibility and diagnostic capability of non-invasive testing.

MEDICA is taking place from 13 – 16 November 2023 in Messe Düsseldorf, Germany. To discover more about Testcard and explore the benefits of partnership, visit their booth at the ABHI UK Pavilion - Hall 16 Stand 16J60.5.

For more information, visit https://testcard.com/.

Exhibitor Data Sheet